PentixaPharm GmbH

Glycotope’s target discovery unit acquisition will double Pentixapharm’s development pipeline, according to the company’s CEO. Image Credit: Vitalii Vodolazskyi / Shutterstock. German radiopharmaceutical biotech Pentixapharm has acquired Germany-based Glycotope’s target discovery unit for an undisclosed sum to expand its oncology pipeline. Pentixapharm plans to turn the preclinical antibodies against multiple cancer targets into radiopharmaceuticals. In addition to the preclinical assets, the company added Glycotope’s laboratories, cell banks, tumour target database, and equipment to its portfolio. “The acquisition will broaden Pentixapharm’s Intellectual Property portfolio beyond the one built around the CXCR4 receptor. This will immediately double the development pipeline and significantly expand the associated business and clinical development opportunities,” explained Pentixapharm CEO Hakim Bouterfa. “Glycotope’s pipeline comprises several candidates that can be used immediately for proof-of-concept studies as next-generation radiopharmaceuticals. We look forward to maximising the synergy of Pentixapharm’s know-how and Glycotope’s target discovery for the benefit of patients in both diagnostics and therapeutic applications.” Pentatixapharm’s clinical pipeline consists of PentixaTher, a Yttrium-90-based treatment for central nervous system lymphoma. The radiotherapy is being evaluated in an open-label Phase I/II dose-finding trial (NCT06132737). The company is also developing a companion diagnostic for PentixaTher, called PentixaFor. The diagnostic is being trialled in a Phase III trial (NCT06125028) for staging of marginal zone lymphoma, a subtype of non-Hodgkin B-cell lymphoma. See Also: Roche gains FDA approval for Vabysmo prefilled syringe Aflibercept biosimilar by Lupin for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval The acquisition will also see around 40 of Glycotope’s staff, including executives, R&D specialists, and administrators, added to Pentixapharm’s employment. While Pentixapharm is currently owned by Eckert & Ziegler (EZAG), a company specialising in providing isotope-related components for medical, scientific and industrial use, it plans to detach from EZAG and list on the Frankfurt Stock Exchange. Radiopharmaceuticals have been an area of interest in the past few years, attracting significant investment and acquisitions. Eli Lilly has signed two high-profile deals for radiopharmaceuticals; a $140m partnership with Radionetics Oncology and a discovery collaboration agreement with Aktis Oncology potentially worth over $1.7bn. Bristol Myers Squibb also jumped on the radiopharmaceuticals trend and paid $4.2bn to acquire RayzeBio . Novartis also shelled out $1.75bn and purchased US-based Mariana Oncology. AstraZeneca also started its radiopharmaceutical pipeline with a $2.4bn acquisition of Fusion Pharmaceuticals in March this year.

7月3日，Pentixapharm是一家处于临床阶段的biotech，致力于发现和开发针对各种恶性肿瘤的新型靶向放射性药物，该公司日前宣布签署一项协议，从7月1日起收购Glycotope GmbH公司的靶点发现业务。 Pentixapharm不是第一家看到Glycotope技术潜力的公司，Evotec、LegoChem Biosciences和第一三共都已与这家德国生物技术公司达成合作。 此项交易包括多种肿瘤靶点的临床前抗体组合，这些抗体可以开发成放射性药物。交易还包括Glycotope的实验室、细胞库、肿瘤靶点数据库、开发发现平台所需的设备，以及一系列专利、许可证和其他有形资产。总之，Pentixapharm将能够增加一支由40名经验丰富的管理人员、研发专家和行政人员组成的综合团队。 作为收购的一部分，Glycotope前首席科学官 (CSO) Patrik Kehler将担任 PentixapharmCSO职务，而Glycotope的前首席执行官Henner Kollenberg将作为首席商务官负责行政和业务发展事宜。 新任命的Pentixapharm首席科学官Patrik Kehler表示：“靶点发现部门的开发活动主要集中在与肿瘤相关的碳水化合物结构，即所谓的 GlycoTargets。与传统抗体相比，它们的主要优势在于减少了与正常组织的结合。基于其卓越的肿瘤特异性，它们适用于各种不同作用模式的开发。在放射性药物领域，它们有可能缩小大多数实体瘤的治疗差距。” "此次收购将扩大Pentixapharm的知识产权组合，使其超越围绕 CXCR4 受体建立的知识产权组合。这将使开发管线立即翻番，并大大拓展相关业务和临床开发机会。"Pentixapharm CEO Hakim Bouterfa解释说：“Glycotope的研发管线包括多个候选药物，可立即用于下一代放射性药物的概念验证研究。我们期待着最大限度地发挥Pentixapharm的专有技术和 Glycotope的靶点发现的协同作用，在诊断和治疗应用中造福患者"。 Pentixapharm是一家成立于2019年的放射性药物开发公司，由Eckert & Ziegler集团全资拥有，该集团是世界上最大的医疗、科学和工业同位素技术提供商之一。Pentixapharm致力于开发基于CXCR4配体的一流放射药物方法，为多种血液癌和实体癌以及心血管和内分泌疾病的诊断和治疗项目提供明确的商业途径。 自去年年底开始，核药赛道热度持续攀升。就在近日，礼来以1.4亿美元首付款引进了Radionetics Oncology的靶向GPCR放射性药物。5月，礼来与Aktis Oncology达成多靶点发现合作协议，旨在利用Aktis专有的基于新型微型蛋白技术放射性药物平台共同开发针对多种实体肿瘤的潜在FIC和差异化治疗方法。 在礼来进军核药之前，诺华、拜耳、强生、BMS等MNC均有在该领域进行布局。其中，诺华和拜耳是当之无愧的领导者，前者通过收购快速搭建起了放射性配体疗法技术平台，同时手握Lutathera和Pluvicto两款畅销产品，后者十年前就推出了Xofigo，而后又大手笔收购Algeta、Noria和PSMA Therapeutics继续加码。 Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。 免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

Evotec, LegoChem Biosciences and Daiichi Sankyo have all signed up to collaborate with Glycotope. Radiopharmaceutical company Pentixapharm is picking up fellow Germany-based Glycotope's target discovery unit for an undisclosed sum in order to double its pipeline courtesy of a portfolio of preclinical cancer antibodies. The assets are aimed at various oncology targets and could be turned into radiopharmaceuticals, Pentixapharm said in a July 3 release. The deal will also see the company take ownership of Glycotope’s labs, cell banks and tumor target database as well as “the equipment needed to exploit the discovery platform, along with a range of patents, licenses, and other tangible assets.” “In total, Pentixapharm will be able to add an integrated team of 40 seasoned executives, R&D specialists, and administrators to its staff,” Pentixapharm said. The release made no mention of the financial terms of the deal. Pentixapharm’s current therapeutic pipeline consists solely of PentixaTher, a CXCR4 cytokine receptor in a phase 1/2 trial for patients with lymphoma affecting the central nervous system. The biotech also has a gallium-68 PET imaging agent being tested in non-Hodgkin B-cell lymphoma and a hypertension-related condition called primary aldosteronism. “The acquisition will broaden Pentixapharm’s intellectual property portfolio beyond the one built around the CXCR4 receptor,” Pentixapharm CEO Hakim Bouterfa said in today’s release. “Glycotope’s pipeline comprises several candidates that can be used immediately for proof-of-concept studies as next generation radiopharmaceuticals,” Bouterfa added. “We look forward to maximizing the synergy of Pentixapharm’s know-how and Glycotope’s target discovery for the benefit of patients in both diagnostics and therapeutic applications.” Pentixapharm is owned by Eckert & Ziegler (EZAG), a specialist in isotope-related components used for nuclear medicine and radiation therapy. But the company’s plans involve detaching from its parent company and listing on the Frankfurt Stock Exchange. “The transaction provides Pentixapharm not just with a chance to build a clinical pipeline beyond the company’s current CXCR4-ligand based programs, but also substantially strengthens its administrative and managerial capacities,” Andreas Eckert, chairman of the supervisory board of both Pentixapharm and EZAG, said in the same release. “The offices and laboratories included in the deal are large enough to allow a consolidation of all Berlin-based activities into one location.” As part of the acquisition, Bouterfa will move across to the biotech’s supervisory board, with current Chief Medical Officer Dirk Pleimes, M.D., taking on the CEO role. Glycotope’s chief scientific officer Patrik Kehler will take up the same role at Pentixapharm. At Glycotope, Kehler and his team have been working on tumor-associated carbohydrate structures, so-called GlycoTargets. Due to the greater ability to target tumors when compared to conventional antibodies, the company’s hope had been to “close the treatment gap that exists for the majority of solid tumors,” Kehler said in the release. The radiopharma space has seen a frenzy of dealmaking since the end of last year, with Eli Lilly making its latest move earlier this week via a $140 million partnership with Radionetics Oncology. Pentixapharm is far from the first company to see potential in Glycotope’s tech. Evotec, LegoChem Biosciences and Daiichi Sankyo have all signed up to collaborate with the German biotech.